Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

Mayo Clinic

Status: Completed

Conditions: Sellar and Suprasellar Masses; Pituitary Tumor

Study type: Observational

Funder types: Other

Identifiers

NCT04369703

19-010785

Details and patient eligibility

About

1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy.
2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy
3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.

Full description

Patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in EDTA tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the morning following surgery).

Enrollment: 199 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

* Patients with sellar and suprasellar masses who undergo neurosurgical procedure at Mayo Clinic Rochester.

Exclusion criteria

* Patients with preexisting CDI.